Hexarelin vs PEG-MGF
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Examorelin, HEX
Hexarelin is a synthetic six-amino-acid peptide (a growth hormone-releasing peptide, or GHRP) that pushes the pituitary to release growth hormone. What makes it more interesting than its cousins is a second job: it binds a receptor in heart tissue and appears to protect the heart, an effect that does not depend on growth hormone at all. It is a research compound, not an approved drug, and almost all of the heart data is from animals.
Also: Pegylated MGF, PEGylated Mechano Growth Factor
PEG-MGF is MGF (the synthetic E-domain peptide from the IGF-1Ec splice variant) with a polyethylene glycol chain attached to make it last longer in the body. That is the theory, anyway. We have to be blunt: there is essentially no published research on PEG-MGF itself. A 2026 clinical review of growth-axis peptides put it in its lowest evidence tier, with no peer-reviewed human studies and no published half-life. Everything said about it online is borrowed from MGF lab work, and MGF's own evidence is shaky.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- Hexarelin has stronger research evidence (Human Trials) compared to PEG-MGF (Limited Research).
Detailed Comparison
| Attribute | Hexarelin | PEG-MGF |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Hexarelin acts through two different receptors, which is the key to understanding it. The first is the growth hormone secretagogue receptor (GHS-R1a), the ghrelin receptor in the pituitary, which is how it triggers growth hormone release. The second is CD36, a scavenger receptor found on heart muscle cells and small blood vessels, and this is where its cardioprotective story lives. Activating CD36 in the heart has been shown to improve coronary flow and protect heart tissue from ischemia (low oxygen) and reperfusion injury, and crucially these effects still happen in growth-hormone-deficient animals, proving the heart benefit is separate from the GH benefit. | Pegylation is a real, well-understood drug technique: attaching PEG makes a molecule bigger, slows how fast the kidneys clear it, and shields it from enzymes. It works for approved drugs, and a pegylated version of full IGF-1 (a different molecule) showed a half-life of 140 to 200 hours in a 2017 first-in-human study. The pitch for PEG-MGF is that the same trick lets the short-lived MGF peptide circulate long enough to act on muscle throughout the body. But PEG also changes how a molecule binds and where it goes, so effects reported for unmodified MGF cannot simply be assumed to carry over. The 2026 review made exactly that point. And since the underlying MGF mechanism was not reproduced in a 2014 pharma study, PEG-MGF is a modification of a hypothesis. |
| Common Dosing | 100-200 mcg 2-3x daily 2-3x daily | 200-400 mcg 2-3x per week (forum-reported) 2-3x weekly in forum protocols |
| Administration | Subcutaneous injection | Subcutaneous or intramuscular injection (forum-reported) |
| Typical Duration | 4-8 weeks (desensitization occurs) | Forum protocols describe 8-16 week cycles with about 4 weeks off; no studied duration exists |
| Best Time to Take | Morning and before bed (fasted) | Not established (forums suggest post-workout) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The growth hormone-releasing effect of hexarelin is well established in humans from older endocrine research, but the exciting cardiovascular claims are still mostly preclinical. The landmark mechanistic work (Circulation Research, 2002) identified CD36 as the receptor through which growth hormone-releasing peptides act on the heart, and follow-up rodent studies showed hexarelin improves left ventricular function and protects cardiomyocytes from ischemia-reperfusion injury, in one case through interleukin-1 signaling (2017). A 2014 review in the Annals of the New York Academy of Sciences and a 2017 PMC review both lay out a plausible cardioprotective case. But here is the honest part: there are no large modern human trials showing hexarelin treats or prevents heart disease in people, and a known limitation is rapid tolerance, the GH response fades with continued use. So the cardiac angle is genuinely interesting biology, not an established therapy. | Searching PubMed for PEG-MGF returns essentially one relevant hit: a 2026 narrative review in Frontiers in Endocrinology (Dominikowski and colleagues) on performance peptides that target the GH and IGF-1 axis. It rated PEG-MGF tier D: no peer-reviewed human studies, no reported route of administration in clinical research, half-life not reported, and safety concerns that are theoretical (based on MGF's link to cancer-cell growth in lab studies). The doses that circulate come from bodybuilding forums, which the review summarized only so doctors can recognize what patients are doing, not as guidance. Everything else people cite is MGF research: cell and animal studies suggesting muscle and heart repair effects, plus a careful 2014 study by Fornaro and colleagues that found no effect of MGF on muscle cells, and no effect of native or stabilized MGF on a separate signaling readout in heart cells. If you are looking for evidence that PEG-MGF builds muscle in humans, it does not exist yet. |
Frequently Asked Questions: Hexarelin vs PEG-MGF
What is the difference between Hexarelin and PEG-MGF?
Hexarelin is a growth hormone peptide that hexarelin is a synthetic six-amino-acid peptide (a growth hormone-releasing peptide, or ghrp) that pushes the pituitary to release growth hormone. what makes it more interesting than its cousins is a second job: it binds a receptor in heart tissue and appears to protect the heart, an effect that does not depend on growth hormone at all. it is a research compound, not an approved drug, and almost all of the heart data is from animals. PEG-MGF is a growth hormone peptide that peg-mgf is mgf (the synthetic e-domain peptide from the igf-1ec splice variant) with a polyethylene glycol chain attached to make it last longer in the body. that is the theory, anyway. we have to be blunt: there is essentially no published research on peg-mgf itself. a 2026 clinical review of growth-axis peptides put it in its lowest evidence tier, with no peer-reviewed human studies and no published half-life. everything said about it online is borrowed from mgf lab work, and mgf's own evidence is shaky. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Hexarelin or PEG-MGF?
Neither is universally "better" - the choice depends on your specific goals. Hexarelin is typically used for growth hormone purposes, while PEG-MGF is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Hexarelin and PEG-MGF be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Hexarelin and PEG-MGF together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.